Large gap with delayed quotes
|
Last quote
02/28/2026
-
02:00:00
|
Bid
02/27/2026 -
21:59:58
|
Bid Volume |
Ask
02/27/2026 -
21:59:58
|
Ask Volume |
|---|---|---|---|---|
|
198.31
+2.14
(
+1.09% )
|
197.80
|
200 |
198.50
|
100 |
Analysis date: 24.02.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 05.12.2025.
Interest
None
None
No stars since 06.02.2026.
Earnings Rev Trend
Negative
Negative
Compared to seven weeks ago, the analysts have lowered their earnings per share estimates. This negative trend began 30.01.2026 at a price of 192.10.
Evaluation
Overvalued
Overvalued
Based on its growth potential and our own criteria, we believe the share price is currently moderately overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 30.01.2026.
4wk Rel Perf
-5.67%
-5.67%
The four-week dividend-adjusted underperformance versus SP500 is 5.67%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 05.12.2025.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -0.54%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 2.97%.
Mkt Cap in $bn
3.72
3.72
With a market capitalization between $2 & $8bn, LIGAND PHARMA is considered a mid-cap stock.
G/PE Ratio
0.84
0.84
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) below 0.9 indicates that investors must pay a premium for the estimated growth potential:
LT P/E
19.55
19.55
The estimated PE is for the year 2027.
LT Growth
16.44%
16.44%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
0.00%
0.00%
The company is not paying a dividend.
Beta
81
81
For 1% of index variation, the stock varies on average by 0.81%.
Correlation
0.43
0.43
42.77% of stock movements are explained by index variations.
Value at Risk
45.36
45.36
The value at risk is estimated at USD 45.36. The risk is therefore 24.00%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
29.08.2014
29.08.2014